O'Conner's Vaporizer in a Bottle
Executive Summary
Company requests a three-month extention of Aug. 14 deadline for filing new data to demonstrate bioequivalence to Richardson-Vicks Vaporub for a Catagory I antitussive claim in the tentative final monograph for cough/cold combinations. Following a Feb. 14 meeting with the agency ("The Pink Sheet" Feb. 29, T&G-9), O'Conner submitted data and a protocol for a proposed in vitro study comparing the vapor concentrations of its Vaporizer in a Bottle and Vicks Vaporub in May. The company said that since it has not received a response to the protodcol from FDA, it is requesting the three month extention.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.